Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Language
Publication year range
1.
Pathobiology ; 83(6): 316-326, 2016.
Article in English | LILACS, Sec. Est. Saúde SP | ID: biblio-1024773

ABSTRACT

Background: ADAMTS are metalloproteases with disintegrin and thrombospondin motifs. They are secreted proteases playing a role in biological processes such as inflammation, angiogenesis, and urogenital development. ADAMTS have specific substrates, such as the proteoglycans (PG) versican, aggrecan, and brevican. Despite data indicating a role of ADAMTS in tumor invasion and metastases, effects played by these molecules in cancer progression are still controversial. In ovarian cancer, the importance of ADAMTS gene mutations was recently described and related to chemotherapy outcome. Objective: To analyze protein levels of ADAMTS-1, -4, and -5, and TIMP-3 in human ovarian cancer classified as benign, borderline, or malignant. We also assessed the expression of the ADAMTS substrates aggrecan, brevican, and versican in these neoplasms. Correlations between overall survival and protein expression were performed. Methods: Tumors were classified according to the WHO Classification of Tumors of Female Reproductive Organs. Protein and PG expression was studied by immunohistochemistry. Differences in labeling were analyzed by percent measurements of stained areas. Results: ADAMTS-1, ADAMTS-5, and its tissue inhibitor TIMP-3 are increased in borderline and malignant tumors compared to benign neoplasms. Aggrecan and versican levels were increased in malignant subtypes compared to benign ovarian cancer. Higher ADAMTS-1, TIMP-3, and versican expression was associated with a shorter overall survival. Conclusions: Comparison of protease, TIMP-3, and substrate expression showed that in malignant tumors all ADAMTS and TIMP-3 expression levels were significantly raised compared to the substrates studied.


Subject(s)
Ovarian Neoplasms , Humans , Biomarkers, Tumor/metabolism , Gene Expression Regulation, Neoplastic , Neoplasms, Glandular and Epithelial/diagnosis , Tissue Inhibitor of Metalloproteinase-3/metabolism , ADAMTS1 Protein/metabolism , ADAMTS4 Protein/metabolism , Carcinoma, Ovarian Epithelial
2.
J Cell Physiol ; 230(8): 1770-80, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25502508

ABSTRACT

MicroRNAs (miRNAs) are important regulators of several cellular processes. During hematopoiesis, specific expression signatures have been reported in different blood cell lineages and stages of hematopoietic stem cell (HSC) differentiation. Here we explored the expression of miRNAs in umbilical cord blood stem (HSC) and progenitor cells (HPC) and compared it to unilineage granulocyte and granulo-monocyte differentiation as well as to primary blasts from patients with acute myeloid leukemia (AML). CD34 + CD38- ad CD34 + CD38 + cells were profiled using a global array consisting of about 2000 miRNAs. An approach combining bioinformatic prediction of miRNA targets with mRNA expression profiling was used to search for putative biologically enriched functions and networks. At least 15 miRNAs to be differentially expressed between HSC and HPC cell population, a cluster of 7 miRNAs are located in the q32 region of human chromosome 14 (miR-377-3p, -136-5p, 376a-3p, 495-3p, 654-3p, 376c-3p and 381-3p) whose expression decreased during the early stages of normal myelopoiesis but were markedly increased in a small set of AML. Interestingly, miR-4739 and -4516, two novel microRNA whose function and targets are presently unknown, showed specific and peculiar expression profile during the hematopoietic stem cells differentiation into unilineages and resulted strongly upregulated in almost all AML subsets. miR-181, -126-5p, -29b-3p and -22-3p resulted dis-regulated in specific leukemias phenotypes. This study provides the first evidence of a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes.


Subject(s)
Cell Differentiation/genetics , Fetal Blood/cytology , Hematopoietic Stem Cells/cytology , Leukemia, Myeloid, Acute/genetics , MicroRNAs/genetics , Transcriptome/genetics , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , Computational Biology , Humans , Oligonucleotide Array Sequence Analysis , Real-Time Polymerase Chain Reaction
3.
Toxicon ; 39(8): 1141-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11306124

ABSTRACT

Systemic skeletal muscle necrosis induced by crotoxin, the major component of the venom of Crotalus durissus terrificus, was investigated. Mice received an intramuscular injection of crotoxin (0.35mg/kg body weight) into the right tibialis anterior (TA) muscles, which were evaluated 3h, 24h and 3 days later. Control mice were injected with saline. Right and left TAs, gastrocnemius, soleus and right masseter and longissimus dorsi were removed and frozen. Histological sections were stained with Toluidine Blue or incubated for acidic phosphatase reaction. Three and 24h after the injection, signals of muscle fiber injury were found: (a) in the injected TA muscles; (b) in both right and contralateral soleus and red gastrocnemius; and (c) in the masseter muscles. Contralateral TA, longissimus dorsi and white gastrocnemius muscles were not injured. In conclusion, crotoxin induced a systemic and selective muscle injury in muscles or muscle regions composed by oxidative muscle fibers.


Subject(s)
Crotoxin/toxicity , Muscle, Skeletal/drug effects , Animals , Female , Injections , Mice , Muscle, Skeletal/pathology , Necrosis , Oxidation-Reduction
4.
Health Prog ; 69(8): 40-4, 1988 Oct.
Article in English | MEDLINE | ID: mdl-10290384

ABSTRACT

A useful tool to assist management with complex multiple-criteria decision making is the analytic hierarchy process (AHP) microcomputer program. The AHP requires the user to judge the relative importance of each criterion, then specify a preference for each alternative relative to each criterion. The result is a prioritized overall ranking of the decision alternatives. Providence Ventures, Inc., used the AHP to assist a recent hospital client in selecting a magnetic resonance imaging vendor. A committee was appointed to narrow the decision alternatives down to three vendors, using the following criteria: price, technology, sitting, service, service contract, cryogen contract, and patient comfort. A key factor in the AHP is establishing priorities and preferences through the pairwise comparison procedure. The program asks the user, for example, if price and technology are equally important. If the response is no, the user tells the program which is more important and by how much, assigning a weight to each criterion. Similarly the user enters pairwise preferences for the vendors in regard to each criterion. The program then computes the overall decision. The entire process takes 10 to 15 minutes. A tool such as the AHP enables the manager and hospital to gain control of resources by saving time in reaching a decision, double checking other decisions for validity, using the model to audit department head decisions, and standardizing the decision-making process.


Subject(s)
Capital Expenditures , Decision Support Systems, Management , Economics , Hospitals , Management Information Systems , Software , Technology, High-Cost , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...